Integrated LC-MS/MS profiling, network pharmacology and experimental validation reveal inhibition of the IL-6/JAK2/STAT3 pathway by Shenqi Compound in comorbid chronic pancreatitis and type 2 diabetes mellitus.
SQC treatment is associated with the suppression of the IL-6/JAK2/STAT3 pathway, accompanied by reduced inflammation, decreased fibrosis, and improvements in both exocrine and endocrine functions in model mice, suggesting that the formula potentially acts as a holistic regulator.